Salute e Benessere
Fluorine-18 Market Size Projected to USD 2.54 Billion by 2031 with 4.7% CAGR, Experiences Growth with Rising Prevalence of Cancer | The Insight Partners
The fluorine-18 market analysis considers various applications of an array of products and services that are expected to contribute to the market performance in the coming years. The report runs an in-depth analysis of market trends, key players, and future opportunities.
:
A significant increase in cases of chronic illnesses such as cancer, cardiovascular diseases (CVDs), and neurological disorders is a major factor contributing to the expansion of the fluorine-18 market. Chronic diseases are becoming more prevalent worldwide. According to the International Agency for Research on Cancer (IARC), cancer cases would rise from ~19.3 million in 2020 to ~30.2 million by 2040. As per the Centers for Disease Control and Prevention, among younger adults, the percentage of those with any chronic condition increased from 52.5% in 2013 to 59.5% in 2023, while the share of people suffering from multiple chronic conditions grew from 21.8% to 27.1% during 2013–2023.
This growth resulted in an additional 5.2 million young adults diagnosed with chronic diseases and 3.8 million more experiencing multiple chronic conditions over the said decade. Thus, the soaring prevalence of colorectal cancer is expected to drive the demand for effective diagnosis and treatment options.
Fluorine-18 is the most commonly utilized radionuclide in positron emission tomography (PET) imaging. It is primarily used in the form of 2-[fluorine 18] fluoro-2-deoxy-D-glucose (FDG), a radiopharmaceutical that allows for the visualization of metabolic functions in tissues. PET scans that utilize FDG-F18 are essential for the diagnosis, staging, and monitoring of various diseases, particularly cancer, neurological issues, and cardiovascular conditions. Advancements in PET/CT technology (such as hybrid imaging) and the creation of more targeted radiopharmaceuticals have improved diagnostic precision. Integrated PET/CT scanners now surpass traditional PET scans in performance, generating a further demand for fluorine-18.
In 2024, North America led the fluorine-18 market with a substantial revenue share, followed by Europe and APAC. Asia Pacific is expected to register the highest CAGR during the forecast period.
The rising prevalence of colorectal cancer and innovations in cancer therapies favor the fluorine-18 market. PET is a widely utilized nuclear medicine imaging technique in clinical environments, as it supports the precise identification, localization, and assessment of various diseases. The World Health Organization (WHO) reports that over 3.6 billion radiology-based diagnostic assessments, 37 million nuclear medicine procedures, and 7.5 million radiotherapy treatments are carried out worldwide each year. According to the European Commission, ~10 million nuclear medicine procedures involving radiopharmaceuticals and imaging technologies are conducted annually in
Europe for disease diagnosis and targeted therapy.
These techniques are also employed across fields such as oncology, immunology, infectious disease research, gastroenterology, cardiology, neurology, and psychiatry. The emergence and introduction of new and more effective radiopharmaceuticals for PET/CT, coupled with the increasing precision of various tumor staging techniques, benefit the fluorine-18 market. For instance, GE HealthCare announced the launch of Flyrcado (flurpiridaz F 18) injection, a unit dose positron emission tomography myocardial perfusion imaging (PET MPI) agent, in the US. The launch was carried out at the 2025 American College of Cardiology (ACC) Annual Scientific Session & Expo, Chicago .
The report from The Insight Partners provides several stakeholders—PDX model developers, academic and research organizations, healthcare facilities, and others—with valuable insights into how to successfully navigate this evolving market landscape and unlock new opportunities.
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Ankit Mathur
ankit.mathur@theinsightpartners.com
Phone: +1-646-491-9876
- https://www.theinsightpartners.com/pr/fluorine-18-market
Logo: https://mma.prnewswire.com/media/2520492/The_Insight_Partners_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/fluorine-18-market-size-projected-to-usd-2-54-billion-by-2031-with-4-7-cagr-experiences-growth-with-rising-prevalence-of-cancer--the-insight-partners-302500203.html